EMAIL THIS PAGE TO A FRIEND

Molecular therapy : the journal of the American Society of Gene Therapy

Gene therapy in patient-specific stem cell lines and a preclinical model of retinitis pigmentosa with membrane frizzled-related protein defects.


PMID 24895994

Abstract

Defects in Membrane Frizzled-related Protein (MFRP) cause autosomal recessive retinitis pigmentosa (RP). MFRP codes for a retinal pigment epithelium (RPE)-specific membrane receptor of unknown function. In patient-specific induced pluripotent stem (iPS)-derived RPE cells, precise levels of MFRP, and its dicistronic partner CTRP5, are critical to the regulation of actin organization. Overexpression of CTRP5 in naïve human RPE cells phenocopied behavior of MFRP-deficient patient RPE (iPS-RPE) cells. AAV8 (Y733F) vector expressing human MFRP rescued the actin disorganization phenotype and restored apical microvilli in patient-specific iPS-RPE cell lines. As a result, AAV-treated MFRP mutant iPS-RPE recovered pigmentation and transepithelial resistance. The efficacy of AAV-mediated gene therapy was also evaluated in Mfrp(rd6)/Mfrp(rd6) mice--an established preclinical model of RP--and long-term improvement in visual function was observed in AAV-Mfrp-treated mice. This report is the first to indicate the successful use of human iPS-RPE cells as a recipient for gene therapy. The observed favorable response to gene therapy in both patient-specific cell lines, and the Mfrp(rd6)/Mfrp(rd6) preclinical model suggests that this form of degeneration caused by MFRP mutations is a potential target for interventional trials.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

WH0083552M1
Monoclonal Anti-MFRP antibody produced in mouse, clone 1E12, purified immunoglobulin, buffered aqueous solution
N5535
Niacinamide, meets USP testing specifications
C6H6N2O
PHR1033
Niacinamide, Pharmaceutical Secondary Standard; Certified Reference Material
C6H6N2O
1462006
Niacinamide, United States Pharmacopeia (USP) Reference Standard
C6H6N2O
72340
Nicotinamide, ≥99.5% (HPLC)
C6H6N2O
N3376
Nicotinamide, ≥98% (HPLC), powder
C6H6N2O
N0636
Nicotinamide, BioReagent, suitable for cell culture, suitable for insect cell culture
C6H6N2O
72345
Nicotinamide, ≥98.5% (HPLC)
C6H6N2O
N0600000
Nicotinamide, European Pharmacopoeia (EP) Reference Standard
C6H6N2O
T0625
Taurine, ≥99%
C2H7NO3S
T8691
Taurine, cell culture tested, meets USP testing specifications
C2H7NO3S
T4571
Taurine, PharmaGrade, Ajinomoto, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture
C2H7NO3S
PHR1109
Taurine, Pharmaceutical Secondary Standard; Certified Reference Material
C2H7NO3S
86329
Taurine, BioUltra, ≥99.5% (T)
C2H7NO3S
W381306
Taurine, ≥98%, FG
C2H7NO3S
1643361
Taurine, United States Pharmacopeia (USP) Reference Standard
C2H7NO3S
SAB2101473
Anti-MFRP antibody produced in rabbit, affinity isolated antibody
SAB2105447
Anti-MFRP, (N-terminal) antibody produced in rabbit, affinity isolated antibody